Table 3 Survival (OS, PFS, and GRFS) and cumulative incidences of NRM, RI, and GvHD according to HLA matching at one, two and three years after allo-SCT.
MSD | MUD | HID | ||||
|---|---|---|---|---|---|---|
At one year | % | 95%CI | % | 95%CI | % | 95%CI |
OS | 54.78 | [44.56–67.34] | 58.88 | [51.08–67.87] | 35.42 | [24.71–51.89] |
PFS | 39.97 | [30.30–52.74] | 50.20 | [42.38–59.46] | 31.25 | [20.54–47.54] |
GRFS | 31.91 | [22.90–44.48] | 35.47 | [28.18–44.64] | 27.08 | [17.03–43.08] |
aGvHD grade 2–4 | 18.99 | [10.28–27.70] | 34.31 | [26.32–42.29] | 37.50 | [23.60–51.40] |
cGvHD | 29.44 | [18.97–39.91] | 31.19 | [23.22–39.16] | 22.92 | [10.81–35.03] |
NRM | 19.58 | [10.59–28.56] | 18.57 | [11.96–25.19] | 33.33 | [19.76–46.91] |
RI | 40.45 | [29.29–51.61] | 31.23 | [23.33–39.12] | 35.42 | [21.65–49.18] |
At Two years | ||||||
OS | 34.99 | [25.32–48.34] | 47.18 | [39.24–56.71] | 23.77 | [14.04–40.22] |
PFS | 28.28 | [19.34–41.36] | 43.10 | [35.29–52.64] | 20.00 | [11.20–35.71] |
GRFS | 20.37 | [12.69–32.70] | 29.48 | [22.54–38.55] | 15.62 | [7.91–30.88] |
cGvHD | 31.06 | [20.34–41.78] | 37.77 | [29.33–46.20] | 25.00 | [12.49–37.51] |
NRM | 21.35 | [11.88–30.81] | 21.98 | [14.83–29.12] | 33.33 | [19.76–46.91] |
RI | 50.38 | [38.50–62.25] | 34.92 | [26.65–43.19] | 46.67 | [31.96–61.37] |
At Three years | ||||||
OS | 26.66 | [17.83–39.85] | 42.25 | [34.32–52.02] | 19.80 | [10.48–37.42] |
PFS | 21.21 | [13.21–34.07] | 40.12 | [32.33–49.78] | 20.00 | [11.20–35.71] |
GRFS | 13.58 | [7.31–25.24] | 27.51 | [20.69–36.58] | 15.62 | [7.91–30.88] |
cGvHD | 32.67 | [22.72–43.63] | 37.77 | [29.33–46.20] | 25.00 | [12.49–37.51] |
NRM | 21.35 | [11.88–30.81] | 23.99 | [16.50–31.47] | 33.33 | [19.76–46.91] |
RI | 57.45 | [45.43–69.46] | 35.90 | [27.53–44.27] | 46.67 | [21.65–49.18] |
